Hims Agrees to Stop Selling Compounded Lilly Obesity Drugs as Zepbound and Foundayo Join Platform

Hims will sell Lilly’s Zepbound and Foundayo directly while ending compounded copies of the company’s obesity drugs on its platform. Patients buying elsewhere still face quality and dosing risks.